ischemic stroke
Conditions
Interventions
Interventional arm:rhPro-UK: 35 mg (5 mg per vial, 7 vials in total)
standard medical treatment:Standard antiplatelet or anticoagulant treatment at the discretion of local investigators
Sponsors
Beijing Tiantan Hospital, Capital Medical University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1. Age >= 18 years, any gender; 2. Acute ischemic stroke symptom onset within 4.5 hours prior to enrollment; onset time refers to last normal time'; 3. Pre-stroke mRS score <= 1; 4. Baseline NIHSS <= 5 (both included); 5. Written informed consent from patients or their legally authorized representatives
Exclusion criteria
Exclusion criteria: 1. Rapidly improving symptoms at the discretion of the investigator; 2. Intended to proceed to endovascular treatment during 90 days (including mechanical thrombectomy, stent insertion or balloon expansion); 3. Allergy to rhPro-UK and its components (human albumin, mannitol); 4. NIHSS consciousness score 1a >2, or epileptic seizure, hemiplegia after seizures (Todd's palsy) or combined with other nervous/mental illness unable to cooperate or unwilling to cooperate; 5. Persistent blood pressure elevation (systolic =180 mmHg or diastolic >= 100 mmHg), despite blood pressure lowering treatment; 6. Blood glucose 22.2 mmol/L (on random glucose testing is acceptable); 7. Active internal bleeding or at high risk of bleeding, e.g.: Major surgery, trauma or gastrointestinal or urinary tract haemorrhage within the previous 21 days, or arterial puncture at a non-compressible site within the previous 7 days; 8. Any known impairment in coagulation due to comorbid disease or anticoagulant use. If on warfarin, thenINR >1.7 or prothrombin time >15 seconds; if use of any direct thrombin inhibitors or direct factor Xa inhibitors or new oral anticoagulants (NOAC) during the last 48 hours unless reversal of effect can be achieved with a reversal agent (by idarucizumab) or sensitivity laboratory test values greater than the upper limit of normal (eg, activated partial thromboplastin time (aPTT), international normalized ratio (INR), platelet count, thrombin time (TT), or appropriate factor Xa activity assay); if on any full dose heparin/heparinoid during the last 24 hours or with an elevated aPTT greater than the upper limit of normal; 9. Known defect of platelet function or platelet count below 100,000/mm3 (but patients on antiplatelet agents can be included); 10. Ischemic stroke or myocardial infarction in previous 3 months, previous intracranial haemorrhage, severe traumatic brain injury or intracranial or intraspinal operation in previous 3 months, or known intracranial neoplasm (except for neuroectodermal tumors, such as meningiomas), arteriovenous malformation or giant aneurysm; 11. Any terminal illness such that patient would not be expected to survive more than 1 year 12. Large cerebral infarction (infarct size > 1/3 MCA territory) on CT or MRI; 13. Acute or past intracerebral hemorrhage (ICH) identified by CT or MRI (including intraparenchymal hemorrhage, intraventricular hemorrhage, subarachnoid hemorrhage, subdural/epidural hematoma); 14. Pregnant women, nursing mothers, or reluctant to agree taking effective contraceptive measures during the period of trial subjects; 15. Any condition that, in the judgment of the investigator could impose hazards to the patient if study therapy is initiated or affect the participation of the patient in the study; 16. Participation in other interventional clinical trials within the previous 3 months.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The proportion of the modified Rankin Scale score (mRS) = 1 at 90 days.; | — |
Secondary
| Measure | Time frame |
|---|---|
| Ordinal distribution of mRS at 90 days;;The proportion of mRS score = 2 at 90 days; ;Clinical response rate at 24 hours defined as an improvement on NIHSS score = 4 points compared with the initial deficit or NIHSS score = 1 point;The rate of symptomatic intracranial hemorrhage within 36 hours;Mortality at 90 days;;Systematic bleeding at 90 days ;Adverse events (AEs)/ serious adverse events (SAEs) within 90 days.; | — |
Countries
China
Contacts
Public ContactYongjun Wang
Beijing Tiantan Hospital, Capital Medical University
Outcome results
None listed